Observational studyOrphanet journal of rare diseases2025
Medical expenses and care pathways of patients with Pompe receiving myozyme: an observational study based on the French national healthcare database.
Observational study in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPompe disease is a rare, severe genetic multisystem disorder. It was one of the first genetic muscle diseases to benefit from an innovative therapy-enzyme replacement therapy (ERT)-more than 15 years ago. Despite this progress, data on patient management in community healthcare settings remain scarce, yet essential to understanding the dual economic and clinical burden of the disease. In this context, the French national healthcare claims database offers a valuable resource for comprehensive data collection. To our knowledge, this study is the first to provide a detailed, patient-level analysis of healthcare resource utilization for patients with Pompe disease. Our objective was to estimate the number of patients receiving ERT with alglucosidase alfa (Myozyme®), describe their care pathways, and assess associated medical expenses in both community settings and healthcare facilities across France.
methodCases of Pompe disease were identified using the French national healthcare claims database aims for expensive drugs. All patients with at least one hospitalization for ERT with Myozyme® in France in 2022 were included. Healthcare resource utilization in 2022 was documented, and costs were assessed from the perspective of public health insurance. Costs drivers were analyzed using a generalised linear model. A supplementary analysis using 2023 data was also conducted.
resultsA total of 154 patients were analyzed, including 24 with classic infantile-onset Pompe disease (IOPD) and 130 with late-onset Pompe disease (LOPD), with a mean age of 48.0 years. The annual healthcare cost per patient was €232,117 for IOPD patients and €358,768 for LOPD patients, nearly 96% of the costs were incurred inside hospitals. In addition to the unit cost of Myozyme® and related hospitalization, ventilator dependence and female sex emerged as major cost drivers. The 2023 data confirmed the robustness of the main findings, showing no substantial year-specific variations.
conclusionThis study provides robust real-world data to assess both hospital and non-hospital costs associated with Pompe disease in patients treated with Myozyme®. With an average of 81.9 medical or paramedical consultations per year and 49 days of hospitalization in 2022, the clinical burden imposed by Pompe disease is substantial, yet essential for patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.